News from cantargia ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

07:50 BST New Number of Shares and Votes in Cantargia

The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed directed share issue (for further information, see...


20 Mar, 2020, 13:13 GMT Prospectus Relating to the Listing of Shares in Cantargia Published

The prospectus relating to the listing of the shares in the directed issue, which was approved by the extraordinary general meeting of Cantargia on...


16 Mar, 2020, 16:10 GMT Extraordinary General Meeting in Cantargia AB (publ)

On 16 March 2020, the extraordinary general meeting in Cantargia resolved to approve the board's resolution of 19 February 2020 to increase the...


10 Mar, 2020, 07:58 GMT Cantargia Acquires Cellerant IP on IL1RAP

Cantargia AB today announced the acquisition of a patent portfolio from Cellerant Therapeutics Inc covering aspects around the interleukin 1 receptor ...


28 Feb, 2020, 08:01 GMT New Number of Shares and Votes in Cantargia

The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed directed share issue (for further information, see...


27 Feb, 2020, 07:53 GMT Cantargia Publishes Full Year Report for 2019

Cantargia AB's ("Cantargia") full year report for 2019 is now available on the company's web page www.cantargia.com/en/investors/financial-reports....


25 Feb, 2020, 14:45 GMT Cantargia Appoints Dr. Ignacio Garcia-Ribas as Chief Medical Officer

Cantargia AB (publ) (Cantargia) today announced it has appointed Dr. Ignacio Garcia-Ribas as Chief Medical Officer (CMO) of Cantargia from March 1,...


20 Feb, 2020, 10:00 GMT Notice of Extraordinary General Meeting in Cantargia AB (publ)

The shareholders of Cantargia AB (publ) are summoned to an extraordinary general meeting on Monday 16 March 2020 at 16.00 CET at the company's...


19 Feb, 2020, 23:05 GMT Cantargia Has Completed a Directed Share Issue of Approximately SEK 410 Million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS...


19 Feb, 2020, 17:25 GMT Cantargia Announces Intention of a Directed Share Issue

Cantargia AB (publ) ("Cantargia" or the "Company") (Nasdaq Stockholm: CANTA) hereby announces its intention of a placement of shares corresponding to ...


14 Feb, 2020, 11:42 GMT Cantargia Advances Development of CAN04 Through Successful Production Scale Up

Cantargia AB (publ) today announced it has reached an important milestone in the development of its antibody project CAN04, currently in clinical...


05 Dec, 2019, 10:14 GMT Cantargia Selects CAN10 as Development Project in Systemic Sclerosis and Myocarditis

Cantargia AB today announced that its research platform CANxx has progressed with the start of a drug development project, CAN10. The project...


02 Dec, 2019, 10:03 GMT Cantargia Reports Positive Interim Data From Ongoing Phase IIa Combination Study With Antibody CAN04

Cantargia AB today announced the first interim data with antibody CAN04 in combination with chemotherapy in the ongoing phase IIa CANFOUR study. The...


25 Nov, 2019, 14:14 GMT Cantargia AB: Nomination Committee Appointed Ahead of 2020 Annual General Meeting

Cantargia AB (publ) hereby provides notification that the Nomination Committee has been appointed ahead of the 2020 Annual General Meeting, and...


18 Nov, 2019, 07:53 GMT Cantargia Presents Novel Preclinical Data on Antibody CAN04 at PEGS Europe Conference

Cantargia AB today announce that new preclinical data on the antibody CAN04 is presented at the 11th annual PEGS (Protein & Antibody Engineering...


15 Nov, 2019, 12:53 GMT Cantargia Advance Antibody CAN04 Development After Positive pre-IND Meeting

Cantargia AB announced today that the pre-IND meeting regarding the clinical development of antibody CAN04 was held with the US FDA. The purpose of...


15 Nov, 2019, 07:37 GMT Cantargia Publishes Interim Report for Third Quarter 2019

Cantargia AB's ("Cantargia") interim report for the period January until September 2019 is now available on the company's web page...


10 Oct, 2019, 11:30 BST Cantargia Reports Filing of Opposition Against Cantargia Patent in Europe

Cantargia AB today announces that an opposition has been filed against one of the European patents in Cantargia's patent family covering antibody...


04 Sep, 2019, 14:39 BST Cantargia Submits Request for pre-IND Meeting on CAN04 With US FDA

Cantargia AB today announced that a request for a pre-IND meeting with the US FDA has been submitted. The purpose of the meeting is to discuss the...


23 Aug, 2019, 12:09 BST Cantargia Announce Positive Preclinical Data on CAN04 in Bladder Cancer

Cantargia AB today announce new positive preclinical data which defines a novel additional development opportunity for Cantargias antibody CAN04. The ...


23 Aug, 2019, 07:47 BST Cantargia and BioWa Extend Ongoing Collaboration Around the POTELLIGENT® Technology

Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT® Technology for production of...


22 Aug, 2019, 07:55 BST Cantargia Publishes Half Year Report

Cantargia AB's ("Cantargia") half year report for the period January until June 2019 is now available on the company's web page...


04 Jul, 2019, 08:01 BST Cantargia Announce Full Recruitment of CAN04 Monotherapy arm in Ongoing Phase IIa Clinical Trial

Cantargia´s antibody CAN04 (nidanilimab) is investigated in an open label three-armed phase IIa clinical trial, CANFOUR. Here, CAN04 is examined as...


02 Jun, 2019, 17:37 BST Cantargia: Presentation of Phase I Clinical Data on Antibody CAN04 at ASCO

New phase I clinical data on Cantargia´s antibody CAN04 (nidanilimab) were presented today in an oral session at the 2019 ASCO Annual Meeting. Data...


27 May, 2019, 18:06 BST Annual General Meeting in Cantargia AB (publ)

Cantargia's Annual General Meeting on 27 May 2019 resolved in accordance with the following: That no dividend would be paid; To discharge the board...